FDA: evidentiary standards for drug development and approval.
The United States Food and Drug Administration is charged with approving drug treatments that have been shown to be safe and effective. Relevant statutes and regulations provide a legal framework for establishing safety and effectiveness that is sufficiently flexible to ensure that appropriate scientific data are collected for specific treatments targeted to particular diseases. Nonetheless, all clinical trials proposed to establish effectiveness must incorporate common elements in order for the appropriate legal and scientific standards of drug approval to be met. This article will discuss the relevant laws and regulations pertaining to the current effectiveness standard and will discuss the most important clinical trial design elements currently considered acceptable for applications for treatments of neurologic and psychiatric illness.
Katz
Russell
R
Division of Neuropharmacological Drug Products, United States Food and Drug Administration, Rockville, Maryland 20852, USA. katzr@cder.fda.gov
D000818:Animals; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence* / Q000592:standards*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use; D012107:Research Design / Q000331:legislation & jurisprudence / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration
D018696:Neuroprotective Agents
Ann Intern Med. 2000 Sep 19;133(6):455-63
10975964
Ann Intern Med. 2000 Sep 19;133(6):464-70
10975965
Alzheimer Dis Assoc Disord. 1997;11 Suppl 5:S10-21; discussion S37-9
9348423
Epilepsia. 1989;30 Suppl 1:S57-63; discussion S64-8
2673757
Ann Intern Med. 1996 Oct 1;125(7):605-13
8815760
Bull World Health Organ. 2001;79(4):373-4
11357217